Description: Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was founded in 2009 and is headquartered in Oslo, Norway.
Home Page: www.thormedical.no
Karenslyst allE 9C
Oslo,
0278
Norway
Phone:
47 97 41 40 00
Officers
| Name | Title |
|---|---|
| Mr. Jasper Kurth | Chief Executive Officer |
| Mr. Brede Ellingsæter | Chief Financial Officer |
| Dr. Sindre Hassfjell | Chief Technology Officer |
| Mr. Sven Røst | Vice President of Communications |
| Dr. Alf Bjørseth Ph.D. | Senior VP of Business Development & Strategic Advisor |
Exchange: OL
Country: NO : Norway
Currency: Norwegian Krone (kr)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9549 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 5 |